Hümpel, Michael, Dr. rer.nat., Biochemist
Education
1963 – 1965 Study of medicine: Christian-Albrechts-Universität, Kiel
1965 Preclinical examination (“Physikum”)
1965 – 1970 Study of biochemistry: Eberhard-Karls-Universität, Tübingen
1970 Diploma in biochemistry
1970 – 1974 Doctorate studies at the Institute for Medical Molecular Biology, MUZL
1974 Dr.rer.nat. awarded from University of Tübingen, Division of Chemistry

Professional career
1974 – 1980 ‘Academic employee’ in the Department of Biodynamics, Schering AG, Berlin
1980 – 1984 Head of the Department of Pharmacokinetics, Schering AG, Berlin
1985 – 1991 Head of the Main Department of Pharmacokinetics, Schering AG, Berlin
1991 – 1996 Head of the Institute of Pharmacokinetics, Schering AG, Berlin
1996 – 1999 Head of Main Department PK and Development Services Therapeutics, SBU Therapeutics, Schering AG
07.1999 – 12/2001 Advisor of the R&D board member of Schering (Prof. G. Stock), strategic projects (local and global)
2002 – 2003 Advisor to Prof. Stock in science politics and SAG project leader SAG/ PAION to develop 8-PN
1.1.2004 Termination of the working relation with Schering, acting as expert for other companies,
End of 2005 Foundation of own company (KAIROSmed GmbH) for further development of 8-PN (bought from SAG).
End of 2008 Liquidation of KAIROSmed GmbH
End of 2010 Foundation of KAIROSmetics UG (Berlin) for R&D and marketing of cosmetics and topical medical products based on natural compounds; scientific advisor to pharmaceutical companies in Pre-clinical and Clinical
until now development questions

Publications: 78 during the period of 1972 to 2023 (see publication list)
Scientific advice
Mentorship for five PhD`s in pharmacy, medicine and veterinary medicine and three habilitations

Further Education/Congresses
Schering-internal educations in administration and staff management
Visit of numerous international congresses mainly in the area of contraception and HRT
Participation in various scientific seminars

AGAH (up to 2001), GDCH (up to 1999)
Founder (1982) and member (up to 1997) of the PK-task force of seven pharmaceutical companies in Germany
Contacts to Authorities/Organizations
FDA, Regulatory Authorities in Sweden, Netherlands, Germany
WHO, NIH, Population Council
Memberships
Expertise (general)
 Staff Management/Organization/Administration
 Scientific Evaluations of Technologies and Research Projects
Member (1995-2001) of an internal expert team deciding on research projects
Co-founder and sponsor of the PK evaluation program TOPFIT
Head of the working group pharmacogenetics (1999-2001)
Concept and realization of a global information and knowledge platform in genomics
Evaluation and follow-up of more than 350 license offers of therapeutics and biotechnology
Referee for the journal Pharmacology & Toxicology
 + Drug Development+
 Acquisition of Projects or Products
Project evaluations
Preparation and operation of Due Diligence
Design of contract (CDA, LOI, Term-Sheet, Supply)

Expertise (specific)
 Chemical Classes
Steroids
Benzodiazepine receptor ligands
Ergot alcaloid derivatives
Prostaglandines, Prostacyclines
NSAIDs
Bisphosphonates
ß-blocking agents
PDE-inhibitors
Interferons
Anti-metabolites
D-peptides
 Medical Areas
Contraception
HRT/Menopause
M.Parkinson
Rheumatoid Arthritis and related diseases
Multiple Sclerosis
Sleep Disturbances
NHL